Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077374 · ClinicalTrials.gov registry record · Phase 2
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
A Phase 2 study, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT02077374 is a Phase 2 study that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT02077374, a Phase 2 study, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests
Interventions
- OTHER Placebo
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077374
The ClinicalTrials.gov registry entry for NCT02077374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02077374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02077374 about?
NCT02077374 is a clinical study titled "A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases". The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests
What is the current status of trial NCT02077374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2014-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02077374?
The interventions under investigation include: Placebo (OTHER), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT02077374?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.